Impact Biomedical (IBO) Change in Accured Expenses (2022 - 2026)
Impact Biomedical (IBO) posted Change in Accured Expenses of $16000.0 for Q1 2026, up 111.27% on a QoQ basis from -$142000.0 in Q4 2025, and up 33.33% year-over-year from $12000.0 in Q1 2025.
Impact Biomedical (IBO) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Impact Biomedical's Change in Accured Expenses history runs 5 years deep, the most recent figure standing at $16000.0 for Q1 2026.
- Quarterly Change in Accured Expenses rose 33.33% year-over-year to $16000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2000.0 (down 98.75% YoY) and the FY2025 annual result came in at -$2000.0, up 94.29% from the prior year.
- Change in Accured Expenses was $16000.0 for Q1 2026 at Impact Biomedical, up from -$142000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $224000.0 in Q4 2023 and bottomed at -$183000.0 in Q1 2024.
- A 5-year average of $13600.0 and a median of $14000.0 in 2024 frame the typical range for Change in Accured Expenses.
- Peak annual rise in Change in Accured Expenses reached 583.33% in 2024, while the deepest fall reached 1307.69% in 2024.
- Impact Biomedical's Change in Accured Expenses stood at $51000.0 in 2022, then jumped by 339.22% to $224000.0 in 2023, then slumped by 58.48% to $93000.0 in 2024, then slumped by 252.69% to -$142000.0 in 2025, then jumped by 111.27% to $16000.0 in 2026.
- Business Quant data shows IBO's Change in Accured Expenses at $16000.0 in Q1 2026, -$142000.0 in Q4 2025, and $69000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - | -16.74 Mn |
| 10 | Impact Biomedical | 47.43 Mn | 47.41 Mn | - | 16,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16,000.00 |
| Mar 31, 2026 | 16,000.00 |
| Dec 31, 2025 | -142,000.00 |
| Dec 31, 2025 | -142,000.00 |
| Sep 30, 2025 | 69,000.00 |
| Sep 30, 2025 | 69,000.00 |
| Jun 30, 2025 | 59,000.00 |
| Jun 30, 2025 | 59,000.00 |
| Mar 31, 2025 | 12,000.00 |
| Mar 31, 2025 | 12,000.00 |
| Dec 31, 2024 | 93,000.00 |
| Dec 31, 2024 | 93,000.00 |
| Sep 30, 2024 | 41,000.00 |
| Sep 30, 2024 | 41,000.00 |
| Jun 30, 2024 | 14,000.00 |
| Jun 30, 2024 | 14,000.00 |
| Mar 31, 2024 | -183,000.00 |
| Mar 31, 2024 | -183,000.00 |
| Dec 31, 2023 | 224,000.00 |
| Dec 31, 2023 | 224,000.00 |